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Abstract 21 
Coronaviruses have been closely related with mankind for thousands of years. Community-acquired human 22 
coronaviruses have long been recognized to cause common cold. However, zoonotic coronaviruses are now 23 
becoming more a global concern with the discovery of highly pathogenic severe acute respiratory syndrome 24 
(SARS) and Middle East respiratory syndrome (MERS) coronaviruses causing severe respiratory diseases. 25 
Infections by these emerging human coronaviruses are characterized by less robust interferon production. 26 
Treatment of patients with recombinant interferon regimen promises beneficial outcomes, suggesting that 27 
compromised interferon expression might contribute at least partially to the severity of disease. The 28 
mechanisms by which coronaviruses evade host innate antiviral response are under intense investigations. 29 
This review focuses on the fierce arms race between host innate antiviral immunity and emerging human 30 
coronaviruses. Particularly, the host pathogen recognition receptors and the signal transduction pathways 31 
to mount an effective antiviral response against SARS and MERS coronavirus infection are discussed. On 32 
the other hand, the counter-measures evolved by SARS and MERS coronaviruses to circumvent host 33 
defense are also dissected. With a better understanding of the dynamic interaction between host and 34 
coronaviruses, it is hoped that insights on the pathogenesis of newly-identified highly pathogenic human 35 
coronaviruses and new strategies in antiviral development can be derived.   36 
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Introduction 37 
Coronaviruses (CoVs) are classified into four genera, namely alpha-, beta-, gamma- and deltacoronavirus, 38 
under the family of Coronaviridae and the order of Nidovirales (Woo et al., 2012). The first three genera 39 
were previously known as groups I, II and III, respectively (Lau et al., 2006; Zhong et al., 2012). CoVs 40 
have been shown to infect many different hosts including bats, birds, dogs, mice and human (Woo et al., 41 
2009; de Groot et al., 2013). The infections are commonly zoonotic in nature (Chan et al., 2013). In the past 42 
50 years, several human CoVs (HCoVs) were identified. HCoV-229E and HCoV-OC43, belonging to 43 
alpha- and betacoronavirus respectively, were the first two HCoVs identified in the mid-1960s (Tyrrell and 44 
Bynoe, 1965; Hamre and Procknow, 1966; Mclntosh et al., 1967). Healthy individuals infected with either 45 
HCoV-OC43 or HCoV-229E develop illnesses within the range of typical common colds with good 46 
prognosis (Bradburne et al., 1967). Since the identification of these two HCoVs, extensive studies were 47 
conducted to understand their pathogenicity. However, almost all studies showed that HCoV-OC43 and 48 
HCoV-229E caused mild illnesses with high titers of neutralizing antibodies (Bradburne et al., 1967). The 49 
idea of HCoV being a relatively weak respiratory disease-causing agent was therefore presented to the field.   50 
This idea was generally accepted until the outbreak of SARS in 2003. SARS-CoV was the first HCoV 51 
identified to cause acute respiratory distress syndrome (ARDS) (Cheng et al., 2007; Graham et al., 2013). 52 
According to World Health Organization (WHO), a total of 8096 cases from 29 countries were reported 53 
with a case mortality rate of 9.6%. The SARS outbreak changed the landscape of CoV studies entirely and 54 
marked the new era of combating infectious diseases. Tremendous efforts have been put into understanding 55 
SARS-CoV pathogenicity, opening a new page of CoV biology. Despite advances in infection control and 56 
quarantine measures in the past decade, another HCoV causing ARDS was identified in Saudi Arabia as a 57 
novel lineage C betacoronavirus in September 2012 (Zaki et al., 2012). The newly identified HCoV was 58 
later named MERS-CoV. Up to October 2015, 1611 laboratory-confirmed cases were reported to WHO 59 
with 575 related deaths in 26 countries, including a recent outbreak involving 186 cases and 37 deaths in 60 
4 
 
South Korea. MERS-CoV is closely related phylogenetically to two bat CoVs, HKU4 and HKU5, shedding 61 
light on the possible zoonotic reservoir of MERS-CoV (Zaki et al., 2012; Memish et al., 2013). 62 
Together with HCoV-HKU1 identified in 2005 (Woo et al., 2005) and HCoV-NL63 discovered in 2004 63 
(Fouchier et al., 2004; van der Hoek et al., 2004), 6 HCoVs have been documented up to date. These 6 64 
HCoVs present diseases with a range of clinical severity from typical common cold in HCoV-OC43, 65 
HCoV-229E, HCoV-HKU1 and HCoV-NL63 to ARDS in SARS-CoV and MERS-CoV. Why these CoVs 66 
show dramatically different pathogenicity in human is an important but unanswered question in the field. 67 
One model to explain this difference is based on adaptation and host immunity. According to this model, 68 
bats are reservoir of various CoVs. Bat CoVs constantly emerge in human via intermediate hosts such as 69 
civets and dromedaries. Exposure of immunologically naïve human populations to these CoVs commonly 70 
causes severe diseases plausibly due to aberrant activation of innate immunity and lack of immune memory. 71 
When some CoVs become better adapted in human by acquiring the ability to transmit from human to 72 
human readily, pandemics could arise. Meanwhile, as they become fully adapted, the CoVs might only 73 
cause mild diseases in human. Existing evidence supports the origin of HCoV-OC43, HCoV-229E, HCoV-74 
HKU1 and HCoV-NL63 from bats and other animals (Woo et al., 2009; Huynh et al., 2012; Corman et al., 75 
2015). Adaptation and virus-host interaction are also known to be major determinants in CoV pathogenesis 76 
(Pepin et al., 2010; Chan et al., 2013). It will therefore be of great interest to see whether emerging human 77 
CoVs might be particularly capable of evading innate antiviral response while activating pathological 78 
inflammation. In other words, we need to determine whether the more severe clinical presentations might 79 
be accounted for by the specific interaction between host and emerging human CoVs, namely SARS-CoV 80 
and MERS-CoV. In this review, the host innate antiviral response to CoV infection is particularly focused. 81 
In addition, the viral strategies adopted by SARS-CoV and MERS-CoV to subvert innate immunity are also 82 
summarized to provide inspiring insights that may explain the discrepancies in virulence (Figure 1). 83 
 84 
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An overview of CoV biology 85 
CoVs are polycistronic positive-sense single-stranded RNA (ssRNA) viruses with genomes of about 30kb 86 
in size. The 5 most two-thirds of CoV genome encodes polyprotein 1a (pp1a) and pp1ab replicase 87 
polyproteins, which are further cleaved by viral proteases to yield non-structural proteins (nsps), while the 88 
3 end of the genome encodes structural and lineage-specific proteins (Durai et al., 2015). The CoV life 89 
cycle begins with the binding to cellular receptor followed by membrane fusion as well as viral RNA and 90 
protein synthesis in the cytoplasm. The pp1a and pp1ab polyproteins are co-translationally processed 91 
resulting in the formation of the replicase complex. A set of nested subgenomic mRNAs and genomic RNA, 92 
which possess both the same 3 end and a common 5 leader sequence derived from the 5 end of the genome, 93 
is then transcribed. Normally, only the 5 end of each mRNA is translated. Virion assembly is achieved by 94 
budding into intracellular membranes and virion release is accomplished through the secretory pathway 95 
(Cheng et al., 2007; Durai et al., 2015).  96 
The coronaviral spike (S) protein is responsible for binding to specific host receptor on cell surface and 97 
fusing viral envelope with lipid membrane of host upon infection (Bosch et al., 2003; Rota et al., 2003; 98 
Chen et al., 2013). HCoV-NL63 and SARS-CoV from α- and β-genera respectively recognize angiotensin-99 
converting enzyme 2 (ACE2) (Li et al., 2003; Pyrc et al., 2007; Frieman et al., 2008; Chen et al., 2013) 100 
while MERS-CoV infects cells through another cell surface enzyme dipetidyl peptidase 4 (DPP4) (Chen et 101 
al., 2013; Raj et al., 2013). Aminopeptidase N (APN) has also been found to be recognized by some α-102 
genus CoVs like HCoV-229E (Yeager et al., 1992). Cell surface receptor binding dictates species-specific 103 
viral entry as well as tropism. This also confines the direction of cellular antiviral response. We and others 104 
have shown the ability of CoV S proteins to activate unfolded protein response and endoplasmic reticulum 105 
stress (Chan et al., 2006; Fung et al., 2014; Siu et al., 2014b). The activity of S might also be functionally 106 
related to coronaviral perturbation of innate antiviral response including IFN and cytokine production. 107 
 108 
6 
 
Detection of CoV by host innate immune sensors 109 
Pattern recognition receptors (PRRs) constitute an indispensable part of the host innate immune defense 110 
mechanism by the detection of foreign, non-self patterns from invading microbes distinct from host. These 111 
pathogen-associated molecular patterns (PAMPs) are usually biomolecules derived from the surface or 112 
generated during the life cycle of the microbes.  The detection of PAMPs by host PRRs activates innate 113 
immune response including the expression of type I IFNs and cytokines for clearance of invading microbes. 114 
During CoV infection, retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and Toll-like receptors 115 
(TLRs) are believed to bear pivotal importance in stimulating host type I IFN induction. It is therefore 116 
essential to review the sensing mechanism of the PRRs to understand viral evasion mechanisms and provide 117 
insights on the development of potential viral antagonists. 118 
RIG-I-like receptors 119 
After viral entry, CoV genomes are exposed in the cytoplasm for expression of viral proteins, providing an 120 
opportunity for viral RNA sensing by host. RLRs are ubiquitously expressed cytoplasmic RNA helicases 121 
of DExD/H box family responsible for sensing double-stranded RNA (dsRNA) (Yoneyama et al., 2005). 122 
Three types of RLRs have been identified up to now, including RIG-I, melanoma differentiation-associated 123 
gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) (Loo and Gale, 2011). RIG-I and 124 
MDA5 consist of N-terminal caspase activation and recruitment domain (CARD) in two tandem copies, a 125 
central DExD/H box helicase domain and a C-terminal domain (CTD) (Yoneyama et al., 2004, 2005). The 126 
N-terminal CARDs are the effector domain of RLRs to mediate downstream transduction, which is held by 127 
the CTD when unstimulated (Jiang et al., 2011; Kowalinski et al., 2011; Luo et al., 2011). However, in the 128 
presence of residual amount of cytoplasmic dsRNA, RLRs bind to dsRNA through the central DExD/H 129 
box helicase domain and CTD with ATP, causing a conformational change that exposes the N-terminal 130 
CARDs for signal transduction (Yoneyama et al., 2004; Jiang et al., 2011). LGP2 lacking the N-terminal 131 
CARDs is thought to act as co-factor that augments the function of RIG-I and MDA5 (Satoh et al., 2010; 132 
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Bruns et al., 2014). Exposure of CARDs leads to oligomerization of RIG-I or MDA5 to form filamentous 133 
structure (Berke et al., 2012; Peisley et al., 2013; Wu et al., 2013). The CARD filament recruits and further 134 
initiates similar filamentous structure formation of CARD on MAVS, an adaptor protein which further 135 
recruits downstream effectors tumor necrosis factor receptor-associated factor 3 (TRAF3), TANK-binding 136 
kinase 1 (TBK1) and IκB kinase ε (IKKε) (Loo and Gale, 2011; Wu et al., 2014). TBK1 and IKKε form a 137 
complex of activated protein kinase for phosphorylation and activation of not only MAVS adaptor (Liu et 138 
al., 2015a), but also IRF3 transcription factor (Loo and Gale, 2011). Activated IRF3 are phosphorylated, 139 
dimerized and eventually translocated to the nucleus. On the other hand, TRAF2/6 is also recruited to 140 
MAVS for NF-κB activation. Specifically, canonical NF-κB inhibitor IκB is phosphorylated and then 141 
degraded through proteasomes in a ubiquitination-dependent fashion (Loo and Gale, 2011). IκB 142 
degradation exposes nuclear localization signal on NF-κB dimer for nuclear translocation. Activated IRF3 143 
and NF-κB together with other transcription factors including c-Jun assemble the enhanceosome that binds 144 
to IFN-β promoter for IFN-β expression (Ford et al., 2010; Loo and Gale, 2011). Infection with mouse 145 
hepatitis virus induces RIG-I expression. In addition, the activation of type I IFN production by this CoV 146 
in oligodendrocytes requires both RIG-I and MDA5 (Li et al., 2010). Thus, RLRs might play an important 147 
role in the sensing of CoV infection.  148 
Several critical questions concerning RLR recognition of CoVs merit further investigations. First, the role 149 
of RLRs in CoV sensing should be studied in RLR-null and CoV-susceptible cells and animals. When 150 
necessary CRISPR/Cas9 technology might be used to disrupt RLR genes in target cells (Hsu et al., 2014; 151 
Yuen et al., 2015). Second, the CoV PAMPs recognized by RLRs should be identified and characterized. 152 
Particularly, it will be of interest to see whether and how common and highly structured regions in 153 
coronaviral genome, such as the aforementioned 5 leader sequence, might be recognized by RLRs. For 154 
example, a polyuridine motif in the 3 untranslated region of hepatitis C virus genome and the panhandle 155 
structure in RNA viruses such as influenza A virus have previously been shown to be RIG-I agonists (Saito 156 
et al., 2008; Weber et al., 2013; Kell et al., 2015; Liu et al., 2015b). In addition, possible involvement of 157 
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viral proteins such as nucleocapsid (N) in this recognition as in the case of other RNA viruses (Saito et al., 158 
2008; Weber et al., 2013) should also be clarified. Finally, comparative analysis of SARS-CoV, MERS-159 
CoV and other HCoVs for their ability to activate RLRs will shed light on whether RLR activation would 160 
be a critical determinant in CoV virulence.  161 
Toll-like receptors 162 
CoVs have been observed to infect host cells through more than one pathway. While CoV entry by the 163 
fusion of viral envelope and host membrane has been described, the endosomal pathway is still considered 164 
the classical entry pathway for CoVs. In this pathway the activation of S protein cleavage by cathepsin L 165 
and transmembrane serine protease TMPRSS2 occurs in the absence of cell surface proteases in certain cell 166 
types (Shirato et al., 2013; Burkard et al., 2014). In this regard, TLR family may play an essential role in 167 
sensing CoV infection through the endosomal pathway. TLR family was identified as another PRR 168 
homologous to Drosophila Toll receptor (Boehme and Compton, 2004), sensing various PAMPs within the 169 
endosome which leads to induction of cytokines and IFNs. In human, each of the 11 TLRs is known to 170 
specifically recognize a particular PAMP and preferentially resides in either plasma or endosomal 171 
membrane. The cellular localization of TLRs defines their functions in detecting different PAMPs. For 172 
example, TLRs critically involved in viral nucleic acid sensing, including TLR3 for dsRNA, TLR7 and 173 
TLR8 for ssRNA, and TLR9 for unmethylated CpG island of dsDNA viruses, are mainly localized in 174 
endosomal membrane while other members having a role in sensing other biomolecules derived from 175 
microbial surface components localized to plasma membrane of infected cells (Xagorari and Chlichlia, 176 
2008; Kawai and Akira, 2010). TLR family members being type 1 transmembrane proteins share a similar 177 
structure with a single transmembrane domain. TLR specificity is determined by the ectodomain made up 178 
of various number of leucine-rich repeats (LRRs) that bind the corresponding PAMP directly (Boehme and 179 
Compton, 2004). Signal transduction begins with ligand binding to LRRs in the ectodomain, thus recruiting 180 
cytosolic adaptor protein MyD88 with cytoplasmic Toll/IL-1 receptor (TIR) domain by homotypic TIR-181 
TIR domain interaction (Xagorari and Chlichlia, 2008). The TLR-MyD88 complex then recruits and 182 
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activates interleukin 1R-associated kinase (IRAK) by phosphorylation. The activated IRAK then in turn 183 
associates with TRAF6 and activates a series of downstream effectors leading to the activation of a range 184 
of cytokines and IFN-stimulated genes (ISGs), while activation of type I IFN expression by TLR3 is 185 
independent of MyD88 but dependent on TRIF (Boehme and Compton, 2004; Xagorari and Chlichlia, 186 
2008). TLR pathway is significantly involved in the suppression of CoV replication and induction of type 187 
I IFN expression. Mice deficient of either TLR3 or TLR4 were more prone to SARS-CoV pathogenesis 188 
(Mazaleuskaya et al., 2012; Totura et al., 2015). Notably, disruption of either MyD88 or TRIF arm of the 189 
TLR signaling pathway causes lethal SARS-CoV disease, indicating the importance of both arms in host 190 
innate immunity against SARS-CoV (Totura et al., 2015). Full characterization of the role of TLRs in host 191 
innate antiviral response against SARS-CoV and MERS-CoV versus other HCoVs will not only provide 192 
new knowledge about how TLR activation might impact CoV pathogenesis, but might also identify new 193 
strategies for antiviral and vaccine development. For example, synthetic TLR agonists could potentially 194 
serve as antivirals and vaccine adjuvants in the prevention and control of CoVs. 195 
 196 
Host innate immune response against CoV infection 197 
Innate antiviral response is the first line of defense against CoV infection. Type I IFNs are important 198 
antiviral and immunomodulatory agents. Type I IFNs function by binding to IFN-α receptor-1 (IFNAR-1) 199 
and IFNAR-2 receptor complex, thus activating Janus family tyrosine kinase (JAK), leading to the 200 
phosphorylation of signal transducer and activator of transcription (STAT), a family of transcription factors 201 
regulating the expression of ISGs. Activated STAT and IRF9 form IFN-stimulated gene factor 3 (ISGF3), 202 
stimulating expression of ISGs by binding to IFN-stimulated response element (ISRE) in promoters of ISGs 203 
(Levy et al., 2001; Samuel, 2001). Viral induction of ISGs was abrogated in STAT1-/- mice infected with 204 
SARS-CoV. The viral infection could not be cleared resulting in severe disease, extensive lung injury and 205 
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100% mortality (Frieman et al., 2010; Zornetzer et al., 2010). This indicates the importance of STAT1 in 206 
SARS-CoV pathogenesis.  207 
ISGs are the workhorses of the innate antiviral response with diverse functions including direct antiviral 208 
activities and regulation of adaptive immune system (Schneider et al., 2014). For example, IFN-inducible 209 
gene p53 evokes apoptosis in virus-infected cells (Takaoka et al., 2003). IFN-inducible protein kinase PKR, 210 
2′, 5′-oligoadenylate synthetase (OAS) and RNase L are important modulators involved in dsRNA sensing, 211 
viral gene expression and replication. They act sequentially to trigger viral RNA degradation and 212 
suppression of viral activities (Samuel, 2001). Other ISGs encoding antiviral effectors such as Mx proteins, 213 
cholesterol-25-hydrolse, IFITM proteins, TRIM proteins, viperin, tetherin, cGAMP synthase and STING 214 
could also be highly relevant to CoV infection (Schneider et al., 2014; Schoggins et al., 2014; Ma et al., 215 
2015a; Ma et al., 2015b). Inflammatory responses triggered by inflammatory cytokines like tumor necrosis 216 
factor α (TNF-α) and IFN-γ are also found to be IFN-dependent (Samuel, 2001). IFNs do not only exert 217 
antiviral effects through activation of innate immunity but also act as modulators of adaptive immunity. 218 
Adaptive immune response is activated by increased level of IFNs. The levels of major histocompatibility 219 
complex (MHC) proteins class I and II are found up-regulated by IFNs. This facilitates efficient antigen 220 
presentation and hence cellular immune response to CoV infection (Samuel, 1991, 2001; Ivashkiv and 221 
Donlin, 2014). In addition, the roles of non-conventional ISGs including microRNAs, long non-coding 222 
RNAs and alternatively spliced isoforms have been increasingly recognized in recent years (Schneider et 223 
al., 2014). It will be of importance to determine whether SARS-CoV and MERS-CoV might be unique in 224 
ISG activation as suggested in a recent study, which demonstrated that MERS-CoV induces repressive 225 
histone modifications to down-regulate specific subsets of ISGs (Menanchery et al., 2014b). In relation to 226 
this, two areas concerning ISG activation by CoVs might require more attention and research efforts. First, 227 
unbiased and large-scale screening of antiviral ISGs using RNA interference or CRISPR/Cas9 technology 228 
might be carried out to identify key cellular factors that restrict SARS-CoV and MERS-CoV replication 229 
and infection. Second, small-molecule compounds that activate antiviral ISGs could be identified and tested 230 
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for inhibition of SARS-CoV and MERS-CoV replication and infection. For example, establishing the 231 
significance of cGAS and STING in CoV infection might lead to the development of cyclic dinucleotides 232 
such as c-di-GMP and cGAMP as novel anti-CoV agents. 233 
 234 
Evasion of innate immune response by CoV 235 
CoVs have been reported to directly or indirectly suppress IFN production and signaling pathways by a 236 
subset of viral proteins via various mechanisms. In many cases, infected patients have shown diminished 237 
levels of type I IFNs. This is especially true for SARS and MERS patients with severe diseases (Faure et 238 
al., 2014). It was also shown that SARS-CoV and MERS-CoV were capable of evading type I IFN 239 
production and signaling to different extents in cultured cells (Kindler et al., 2013). When the deficiency in 240 
type I IFN production in CoV-infected cells was remedied by IFN-α treatment, CoV replication was 241 
inhibited (Falzarano et al., 2013). Combination of IFN-α with other antiviral drugs further improves the 242 
survival of infected patients (Omrani et al., 2014). This evidence suggests an essential role of type I IFNs 243 
in the antiviral effect against CoV infection. CoVs have evolved strategies to counter host antiviral response 244 
by antagonizing type I IFN production and signaling. CoV proteins have been characterized to exhibit 245 
innate immunosuppressive effects in cellular models. Below we will discuss them in three categories: 246 
structural, lineage-specific and non-structural proteins (nsps) (de Groot et al., 2013). Nsps of CoVs are 247 
involved in the assembly of the replicase complex for viral RNA synthesis (Sevajol et al., 2014). Certain 248 
nsps have also been reported to possess innate immunosuppressive effect that facilitates viral replication 249 
and propagation, although these proteins per se are not required for viral life cycle (Narayanan et al., 2008b; 250 
Lokugamage et al., 2015). Nsps of different CoVs are more or less evolutionarily conserved suggesting 251 
their functional significance, with the exception of nsp1 and nsp2, which are thought to contribute to 252 
virulence of certain CoVs (Neuman et al., 2014). Four structural proteins are found in CoVs, namely S, 253 
membrane (M), envelope (E) and N proteins. Structural proteins contribute the architecture for virion 254 
12 
 
assembly. Accessory proteins are lineage-specific with diverse behaviors in different CoVs but are not 255 
essential for viral replication and propagation (de Groot et al., 2013). 256 
 257 
CoV nsps have shown suppressive effects in various immune pathways including type I IFN production 258 
and signaling. SARS-CoV and MERS-CoV nsp1 proteins have been shown to selectively induce 259 
degradation of host mRNA by inducing endonucleolytic cleavage while leaving viral RNAs intact (Huang 260 
et al., 2011; Lokugamage et al., 2015). In addition to the induction of endonucleolytic cleavage of host 261 
mRNA, general inhibition of host mRNA translation is achieved by binding of 40S subunit of ribosome 262 
with SARS-CoV nsp1 (Huang et al., 2011). Particularly, SARS-CoV nsp1 inhibits innate immune response 263 
by translational repression of IFN mRNA transcripts, hence altering IFN production and signaling 264 
(Narayanan et al., 2008a; Tanaka et al., 2012). MERS-CoV nsp1 has also been characterized to specifically 265 
induce endonucleolytic cleavage of nuclear transcribed mRNA while sparing cytoplasmic host mRNA and 266 
viral RNA (Lokugamage et al., 2015). This suggests a novel mechanism for evading host immune response. 267 
CoV nsp3 protein has been characterized with a papain-like protease (PLpro) domain for enzymatic 268 
cleavage of pp1a and pp1ab as well as a PLP2 domain with deubiquitinating and deISGylating activity 269 
(Clementz et al., 2010; Mielech et al., 2014). MERS-CoV PLpro is able to antagonize IFN production 270 
induced by RIG-I and MDA5 as well as NF-κB activation (Mielech et al., 2014). MERS-CoV PLpro is 271 
catalytically more efficient (Báez-Santos et al., 2014) and its catalytic activity is indispensable for the 272 
suppressive effect on RIG-I, MDA5 and NF-κB (Mielesh et al., 2014). In contrast, SARS-CoV PLpro does 273 
not require enzymatic activity for IFN antagonism (Clementz et al., 2010). HCoV-NL63 and SARS-CoV 274 
PLP2 transmembrane domain can also act as potent IFN antagonists to suppress IFN production induced 275 
by RIG-IN, a dominant active form of RIG-I (Clementz et al., 2010). In another view of direct inhibition 276 
of IFN induction, nsp3 with deubiquitinating and deISGylating activity may also influence the 277 
ubiquitination and ISGylation pattern and dynamics thus indirectly hindering innate immune response 278 
13 
 
against CoV infections (Clementz et al., 2010). For example, ISGylation and ubiquitination of IRF3 279 
required for optimal activation is probably altered by PLP domain of nsp3. 280 
Apart from directly manipulating the signaling pathway involved in IFN production, several CoV nsps were 281 
identified to act on viral RNA to minimize IFN stimulation. N7-methylguanosine is the fundamental moiety 282 
of eukaryotic mRNA cap structure and 2-O-methylation on this moiety is a representative host signature 283 
to avoid PRR activation as well as ISG action. Particularly, viral RNA with this modification evades 284 
recognition by MDA5 or IFIT family antiviral factors (Züst et al., 2011; Daffis et al., 2010). This is a 285 
common immunoevasive mechanism adopted by not only different CoVs but also other RNA viruses. 286 
Functional screening in yeasts suggested a novel function of SARS-CoV nsp14 as a guanine-N7-287 
methyltransferase, the activity of which is required for viral replication and transcription (Chen et al., 2009). 288 
Another nsp of SARS-CoV, nsp16, also possesses 2-O-methyltransferase activity (Menachery et al., 2014a; 289 
Menachery et al., 2014c). Structural modeling suggested that SARS-CoV nsp16 associates with nsp10 in  290 
1:1 ratio to form a complex of mature 2-O-methyltransferase for viral cap methylation (Chen et al., 2011; 291 
Decroly et al., 2011). A short peptide derived from nsp10 conserved region has been shown to be a 292 
promising nsp16 antagonist which outcompetes native nsp10 to blunt 2-O-methyltransferase activity and 293 
restrict viral replication (Wang et al., 2015). Plausibly, CoV nsps might execute their innate 294 
immunosuppressive roles by targeting type I IFN production and signaling. Further investigations are 295 
required to clarify whether and how far the sensing of CoV RNA and the induction of innate antiviral 296 
response are involved in the inhibitory activity of the nsp antagonists on CoV replication. 297 
 298 
CoV structural proteins have been shown to inhibit IFN production and signaling at multiple levels. SARS-299 
CoV N protein showed inhibitory effects on IFN production induced by Sendai virus and dsRNA analogue 300 
poly(I:C) but no inhibition could be observed when downstream signaling molecules of TLR and RLR 301 
pathway were overexpressed. Truncation mutant of N protein shows that the C-terminal domain is critical 302 
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for RNA-binding and IFN-antagonizing effect (Lu et al., 2011). This suggests SARS-CoV N may interfere 303 
with RNA recognition by host immune sensors such as RIG-I and MDA5 thus achieving suppressive role 304 
in IFN production. Other than N protein, SARS-CoV M protein has been characterized to potently down-305 
regulate IFN production by impeding the formation of TRAF3·TANK·TBK1/IKKε complex through the 306 
first transmembrane domain (Siu et al., 2009, 2014a). SARS-CoV M protein inhibits IFN production 307 
possibly through a sequestration model in which components of TRAF3·TANK·TBK1/IKKε complex, an 308 
active complex for IRF3 phosphorylation, are sequestered to specific locations in the cell (Siu et al., 2009). 309 
SARS-CoV M protein therefore exerts its inhibitory effects by impeding the formation of 310 
TRAF3·TANK·TBK1/IKKε complex but not by modulating the catalytic activity of the complex. 311 
MERS-CoV M protein also exhibits IFN-antagonizing effects similar to its counterpart in SARS-CoV. In 312 
a previous study, MERS-CoV M is shown to impede IFN production by preventing IRF3 translocation into 313 
the nucleus (Yang et al., 2013). However, the detailed mechanism of inhibition remains unknown. Recently, 314 
our group has characterized the mode of inhibition of IFN production by MERS-CoV M. Consistently with 315 
previous report, we show that MERS-CoV M suppresses IFN production by preventing IRF3 activation. 316 
We showed that MERS-CoV M interacts with TRAF3 which impedes the recruitment of TBK1 to TRAF3 317 
complex. IRF3 activation and dimerization have also been hampered as a result. The inhibitory effect is at 318 
least in part accounted for by the N-terminal transmembrane domains. Despite of the similar behaviors, 319 
MERS-CoV M can only moderately suppress IFN expression when compared to SARS-CoV M. 320 
Interestingly, HCoV-HKU1 M protein does not exert any inhibitory effects on IFN production (Siu et al., 321 
2014a), suggesting that the IFN-antagonizing activity of structural proteins is unique to each CoV but not 322 
universal. It will be of great interest to see whether this may correlate with the pathogenicity of different 323 
HCoVs. 324 
Eight accessory proteins have been identified in SARS-CoV and five are found in MERS-CoV (Narayanan 325 
et al., 2008b). SARS-CoV genome encodes ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8a, ORF8b and 326 
ORF9b as accessory proteins (Narayanan et al., 2008b). SARS-CoV ORF3b and ORF6 have been found to 327 
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antagonize type I IFN production and signaling. Particularly, SARS-CoV ORF3b and ORF6 suppress IFN-328 
β production by perturbing IRF3 activation induced by Sendai virus infection. SARS-CoV ORF3b and 329 
ORF6 also suppress IFN-β-induced activation of ISRE in ISG promoters (Kopecky-Bromberg et al., 2007), 330 
although they are not able to reduce the level of phosphorylation of STAT1, a transcription factor that 331 
activates ISRE activity once phosphorylated. However, SARS-CoV ORF6 has been shown to inhibit 332 
STAT1 translocation for ISRE activation (Kopecky-Bromberg et al., 2007). The findings suggest a mode 333 
of inhibition of IFN-β signaling by SARS-CoV.  334 
IFN antagonism of accessory proteins has also been observed in another deadly HCoV. MERS-CoV 335 
genome encodes ORF3, ORF4a, ORF4b, ORF5 and ORF8b (de Groot et al., 2013). Among the five 336 
accessory proteins, ORF4a, ORF4b and ORF5 show the ability to dampen IFN production (Yang et al., 337 
2013). Suppression of IFN-β promoter-driven luciferase activity has been observed in cells transfected with 338 
ORF4a, ORF4b and ORF5 plasmids. All these 3 accessory proteins are able to block IRF3 translocation to 339 
the nucleus to activate IFN promoter (Yang et al., 2013). MERS-CoV ORF4a shows an additional level of 340 
inhibition of innate immunity by intervening NF-κB activation. In another study, ORF4a has been shown 341 
as an antagonist of IFN production by inhibiting IRF3 translocation but has no effect on IFN signaling 342 
(Niemeyer et al., 2013). Our group demonstrated that MERS-CoV ORF4a interacts with PACT, a cellular 343 
dsRNA-binding protein that optimally activates RIG-I- and MDA5-induced type I IFN production, in an 344 
RNA-dependent manner (Siu et al., 2014c). This suggests that ORF4a may compete with RIG-I and MDA5 345 
for RNA, rendering the inactivation of RIG-I and MDA5. Direct interaction of ORF4a with PACT may 346 
also prevent interaction of PACT with RIG-I and MDA5, thus compromising PACT-dependent activation 347 
of RIG-I and MDA5 required for optimal induction of IFN production. Although we and others have 348 
observed the IFN-antagonizing activity of MERS-CoV ORF4b, different activity profiles and mechanisms 349 
have been suggested (Yang et al., 2013; Matthews et al., 2014). One recent report suggested that ORF4b 350 
directly interacts with and inhibits TBK1/IKK in the cytoplasm but might also perturb type I IFN 351 
production in the nucleus through an unknown mechanism (Yang et al., 2015).  352 
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Mouse hepatitis virus, another betacoronavirus closely related to HCoV-OC43 and HCoV-HKU1, encodes 353 
a lineage-specific accessory protein named ns2 with innate immunosuppressive property (Zhao et al., 2012). 354 
Biochemical assays indicate that ns2 protein has phosphodiesterase activity against 2, 5-A, the product of 355 
OAS (Zhang et al., 2013). Thus, ns2 is a potent inhibitor of an IFN effector molecule and it might represent 356 
a new family of viral and cellular proteins with innate immunosuppressive activity (Zhang et al., 2013; 357 
Gusho et al., 2014). Whether distantly related proteins in HCoV-OC43 and HCoV-HKU1 might have 358 
similar activity remains to be determined. More importantly, it will be of interest to see whether SARS-359 
CoV and MERS-CoV might encode proteins with similar enzymatic activity.       360 
Multiple IFN antagonists have been identified and characterized in SARS-CoV and MERS-CoV. Some 361 
differences between these IFN-antagonizing viral proteins and their counterparts in other CoVs such as the 362 
parental bat viruses of MERS-CoV have also been noticed (Siu et al., 2014c). Existing evidence supports 363 
several important notions. First, although SARS-CoV and MERS-CoV share some features in common, 364 
they are distinct and use unique mechanisms for innate immune evasion (Perlman and Zhao, 2013). Second, 365 
both SARS-CoV and MERS-CoV are bat-origin CoVs that are well adapted in bats but newly emerge in 366 
human. This provides a golden opportunity for the study of CoV-host interaction, CoV adaptation as well 367 
as the arms race between host innate antiviral immunity and CoVs. Observing how the arms race between 368 
the host and SARS-CoV or MERS-CoV might evolve when the viruses become adapted to human will be 369 
most revealing and could provide important clues as to how a balance of power in this arms race might 370 
result in attenuation with increased transmissibility. Finally, studies on SARS-CoV and MERS-CoV have 371 
overturned existing concepts and derived new principles and thoughts to CoV biology. Particularly, 372 
mechanisms by which SARS-CoV and MERS-CoV evade innate immunity have attracted increasing 373 
attention. However, many key issues remain obscure. Particularly, better in vivo evidence should be 374 
obtained to clarify whether more potent inhibition of innate IFN production and signaling by SARS-CoV 375 
and MERS-CoV is a key determinant in virulence and disease severity. 376 
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 377 
Conclusion 378 
CoVs have drawn a lot of interests in the light of the recent emergence of MERS-CoV. It remains to be 379 
understood whether the emerging deadly CoVs causing ARDS might ultimately be established and adapted 380 
in human resulting in significant attenuation of virulence. From the identification of the first two HCoVs, 381 
HCoV-229E and HCoV-OC43 in the mid-1960s, we learned that HCoV was able to cause only common 382 
cold. However, the outbreaks of SARS and MERS that have claimed hundreds of lives revealed the other 383 
extreme of CoV pathogenicity and raised new questions in CoV biology. So far no vaccines have been 384 
developed against SARS-CoV and MERS-CoV.  385 
Infection with SARS-CoV and MERS-CoV has been accompanied with suppression of innate immune 386 
response, most notably with the suppression of type I IFN production and signaling pathways. As the first-387 
line defense in the immune system, suppression of innate immune response by these CoVs has impeded the 388 
host ability to restrict infection, causing significant casualties. Although many reports have shed light on 389 
the molecular mechanism by which various CoV proteins antagonize type I IFN production and signaling, 390 
most of the studies were performed with overexpression experiments in cellular models. Future emphasis 391 
should be put on the characterization of knock-out viruses with which the function of a particular viral gene 392 
could be studied in a more physiologically relevant context. Infectious clones and replicons for SARS-CoV 393 
and MERS-CoV have been generated for this reverse genetic approach (Yount et al., 2003; Almazán et al., 394 
2006, 2013, 2014; Scobey et al., 2013). IFN and cytokine profiles of deadly HCoVs such as SARS-CoV 395 
and MERS-CoV can be compared with HCoV-229E and HCoV-OC43 causing mild diseases. The pivotal 396 
significance of type I IFNs in innate immune activation and modulation has been discussed in this review. 397 
Suppression pattern of IFN may provide insights on the high pathogenicity of deadly HCoVs. The arms 398 
race between host innate antiviral response and emerging human CoVs might evolve after their introduction 399 
and establishment in human populations, with significant impact on virulence, transmissibility and disease 400 
18 
 
severity. Emerging human CoVs remain a potential threat to global public health. New knowledge about 401 
the host-CoV arms race will provide new ideas, targets and attenuated strains for the design and 402 
development of antivirals and vaccines for prevention and control of deadly CoV infections.  403 
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Figure 1. Innate immune response mediated against coronavirus infection and viral evasion mechanisms.  728 
(Left) Upon CoV infection, viral genome ssRNA as well as dsRNA intermediate found in virus life cycle 729 
are exposed to host innate immune sensors, RIG-I/MDA5 in cytoplasm or Toll-like receptors TLR3/7/8 in 730 
endosome. Activation of these immune sensors initiates a downstream signaling cascade that leads to IFN-731 
β gene expression. RIG-I/MDA5 conveys signal through a mitochondrial adaptor MAVS while TLR signals 732 
through TRIF/MyD88. Both pathways share the common TRAF adaptor to activate transcription factors. 733 
TRAF3 serves as an adaptor which activates TANKTBK1/IKKε complex for IRF3 phosphorylation and 734 
subsequent dimerization, while TRAF6 is responsible for the activation of IKK complex which 735 
phosphorylates the canonical inhibitor of NF-κB (IκB). Activated transcription factors are translocated into 736 
the nucleus to drive IFN-β expression. (Right) IFN-β are secreted into extracellular space and bound to its 737 
cognate receptors IFNAR to activate downstream JAK-STAT signaling. Receptor-associated tyrosine 738 
kinases Jak1 and Tyk2 are brought to juxtaposition for self-phosphorylation and activation. STATs are 739 
recruited to and phosphorylated by the tyrosine kinases. Phosphorylated STAT1/2 with IRF9 forms a 740 
ternary complex ISGF3 which translocates into the nucleus and binds to ISRE in the promoter region 741 
upstream of ISG genes. ISG genes are expressed consequently to establish an antiviral state in cells. OAS 742 
is an example of ISG which produces 2, 5-oligoadenylate (2, 5-A) upon detection of dsRNA and activates 743 
RNase L to cleave viral RNA to yield more RLR ligand as a positive-feedback mechanism of IFN 744 
production. The CoV-encoded proteins shown in red are known to intervene the host innate immune 745 
signaling at various action points as evasion mechanisms to sustain viral replication and propagation. The 746 
action points at which viral proteins function marked with a question mark (?) represent controversial and 747 
inconclusive findings in the field or molecular mechanisms not well studied. MHV: mouse hepatitis virus. 748 

